hero image
Dr. José-Luis Díaz-Ortega - International Federation on Ageing. Cuernavaca, Mor., MX

Dr. José-Luis Díaz-Ortega Dr. José-Luis Díaz-Ortega

Investigador - Departamento de Evaluación de Vacunas del Centro de Investigación Sobre Enfermedades Infecciosas (CISEI) | Instituto Nacional de Salud Pública

Cuernavaca, Mor., MEXICO

Medical Doctor Specializing in Epidemiology and Immunology

Media

Publications:

Documents:

Photos:

Videos:

Dr. José Luis Díaz Ortega Dr. José Luis Díaz Ortega sobre el Primer Consenso Mexicano de Vacunación en el Adulto Dr. José Luis Díaz Ortega Jose-Luis Diaz-Ortega | Instituto Nacional de Salud Pública | Mexico | Vaccines 2015

Audio:

Social

Biography

Medical Doctor (National Autonomous University of Mexico) specializations in Epidemiology and Immunology. He serves as a Researcher and Professor at INSP, and as Secretary of the National Commission for Documentation and Verification of Elimination of Measles, Rubella and Congenital Rubella Syndrome. He has served as consultant for Expanded Program on Immunization at WHO/PAHO headquarters, and some countries of the Americas and Southeast Asia, and participates in the Regional Commission for Certification of Eradication Final Poliomyelitis. He has published 46 scientific articles and 16 book chapters or manuals

Areas of Expertise (7)

Vaccination

COVID-19

Measles

Immunology

Epidemiology

Infant Mortality

Coronavirus

Featured Articles (5)

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 Lancet

II Abubakar, A Banerjee, JL Diaz-Ortega, and T Tillmann

2015

Up-to-date evidence on levels and trends for age-sex-specific all-cause and cause-specific mortality is essential for the formation of global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013) we estimated yearly deaths for 188 countries between 1990, and 2013. We used the results to assess whether there is epidemiological convergence across countries.

view more

Cobertura de vacunación en niños y adolescentes en México: esquema completo, incompleto y no vacunación Salud Pública de México

José Luis Díaz-Ortega, Elizabeth Ferreira-Guerrero, Belem Trejo-Valdivia, Martha María Téllez-Rojo, Leticia Ferreyra-Reyes, María Hernández-Serrato, Airain Alejandra Montoya-Rodríguez, Lourdes García-García

2013

To assess vaccination coverage of children and adolescents. Materials and methods. Study based on National Health and Nutrition Survey 2012. Results. Coverage in < 1 year infants olds infants was < 70% for 3 vaccines and < 50% for 5. In 15-23 months-olds infants coverage was 59.8% for ...

view more

Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis Vaccine

Arnab Acharya, Jose Luis Diaz-Ortega, Gina Tambini, Ciro de Quadros, Isao Arita

2002

In 1994, the Americas set a goal of interrupting indigenous measles transmission from the Western Hemisphere by 2000. To accomplish this goal, the Pan American Health Organization (PAHO) developed an enhanced measles vaccination strategy. Methods: Cost data was collected at PAHO for Latin American and Caribbean (LAC) countries covering 96% of the region’s population on components of the routine programs, and the ‘follow-up’ activities from member countries. In order to interpret our findings we have compared the present scenario regarding measles with one that would have ensued if past trends continued. Results: For the entire LAC population, estimated cost of elimination program will be US$ 571 million in present value terms. Interpretation: The vaccination strategy toward achieving elimination of measles costs US$ 244 million, incremental from the cost of vaccination before the elimination program. Within 2000–2020, the current program will have prevented the occurrence of 3.2 million cases of measles and 16,000 deaths. Thus, vaccination strategy prevents a single case of measles at the cost of US$ 71.75 and prevents a death due to measles at the cost of US$ 15,000. The case fatality rate depends on a well functioning treatment program for measles cases. The vaccination strategy saves a total of US$ 208 million in treatments costs due to reduced incidence of measles.

view more

Recommended childhood immunization schedule--United States, 2000 MMWR. Morbidity and mortality weekly report

JL Diaz-Ortega

2000

Each year, CDC's Advisory Committee on Immunization Practices (ACIP) reviews the recommended childhood immunization schedule to ensure it remains current with changes in manufacturers' vaccine formulations, revisions in recommendations for the use of licensed vaccines, and recommendations for newly licensed vaccines. This report presents the recommended childhood immunization schedule for 2000 and explains the changes that have occurred since January 1999.

view more

Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS Bulletin of the World Health Organization

Felicity T Cutts, Susan E Robertson, JL Diaz-Ortega, R Samuel

1997

Congenital rubella syndrome (CRS) can lead to deafness, heart disease, and cataracts, and a variety of other permanent manifestations. In developing countries, the burden of CRS has been assessed as follows: by surveillance of CRS; by surveillance of acquired rubella; by age-stratified serosurveys; and by serosurveys documenting the rubella susceptibility of women of childbearing age. During rubella outbreaks, rates of CRS per 1000 live births were at least 1.7 in Israel, 1.7 in Jamaica, 0.7 in Oman, 2.2 in Panama, 1.5 ...

view more